A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
about
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasMechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for hInitial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells
P2860
A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@ast
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@en
type
label
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@ast
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@en
prefLabel
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@ast
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@en
P2093
P1476
A phase I and pharmacokinetic ...... h advanced solid malignancies.
@en
P2093
Bernareggi A
Gatineau M
P407
P577
2001-01-01T00:00:00Z